The aims of the proposed research are to critically evaluate, compare and validate selected multi-modality imaging metrics as quantitative (surrogate) biomarkers of the response of breast tumors to specific treatments to provide the scientific basis for their translation into patient management and clinical trials. Recent years have seen a dramatic increase in the range of information available from imaging methods so that a number of techniques are available to quantitatively monitor tumor growth and treatment response. Several of these have been used in both pre-clinical and clinical studies, but with mixed results confounded by lack of standardization, inadequate understanding of underlying mechanisms and absence of appropriate validation to assist their interpretation. We propose to systematically evaluate emerging, clinically-viable imaging metrics in appropriate animal models to establish which combination of methods is most accurate at predicting response to specific treatments that are relevant for breast cancer. The paradigm we have chosen to achieve these ends considers two major categories of human breast cancer, HER2 positive tumors and ER/PR/HER2 triple-negative tumors and both established and emerging therapies. For each category we will assess treatment response by performing longitudinal studies that combine PET, SPECT, and MRI to provide functional assessments of the response of breast tumors to treatment. We will also correlate imaging with histology data to understand the mechanistic underpinnings of the information provided by each type of measurement. We hypothesize that treatment type will determine which imaging metrics are most sensitive to early response. To test this hypothesis we will pursue the following specific aims: 1. [HER2+ cancer] In the BT-474 mouse model of breast cancer with and without resistance to Herceptin (to simulate responders and nonresponders, respectively), measure the effects of treatment response to Herceptin or Herceptin+lapatinib as reported by PET, SPECT, and MRI metrics. This study will also be performed in the polymoma middle T (PyMT) spontaneous mouse model of human breast cancer. 2. [Triple negative cancer] In the MDA-231 mouse model of triple-negative breast cancer with and without resistance to Docetaxel (to simulate responders and nonresponders, respectively), measure the effects of treatment to Docetaxel or Docetaxel+sunitinib as reported by PET, SPECT, and MRI metrics.

Public Health Relevance

We propose to systematically evaluate emerging clinically-viable imaging metrics to establish which methods are most accurate at predicting treatment response with clinically employed breast cancer treatments. In this way we hope to expand the range of quantitative imaging biomarkers that can be implemented in the clinical setting. We hypothesize that treatment type will determine which imaging metrics are the most sensitive to early response enabling specific treatment classes to be paired with specific imaging approaches so that the most sensitive imaging biomarkers can be selected when designing clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA138599-03
Application #
8212366
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Zhang, Huiming
Project Start
2010-05-01
Project End
2015-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
3
Fiscal Year
2012
Total Cost
$453,392
Indirect Cost
$162,756
Name
Vanderbilt University Medical Center
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Li, Xia; Abramson, Richard G; Arlinghaus, Lori R et al. (2015) Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer. Invest Radiol 50:195-204
Bryant, Nathan D; Li, Ke; Does, Mark D et al. (2014) Multi-parametric MRI characterization of inflammation in murine skeletal muscle. NMR Biomed 27:716-25
Hormuth 2nd, David A; Skinner, Jack T; Does, Mark D et al. (2014) A comparison of individual and population-derived vascular input functions for quantitative DCE-MRI in rats. Magn Reson Imaging 32:397-401
Barnes, Stephanie L; Quarles, C Chad; Yankeelov, Thomas E (2014) Modeling the effect of intra-voxel diffusion of contrast agent on the quantitative analysis of dynamic contrast enhanced magnetic resonance imaging. PLoS One 9:e108726
Wilson 3rd, George H; Gore, John C; Yankeelov, Thomas E et al. (2014) An Approach to Breast Cancer Diagnosis via PET Imaging of Microcalcifications Using (18)F-NaF. J Nucl Med 55:1138-43
Seeley, Erin H; Wilson, Kevin J; Yankeelov, Thomas E et al. (2014) Co-registration of multi-modality imaging allows for comprehensive analysis of tumor-induced bone disease. Bone 61:208-16
Zhu, He; Arlinghaus, Lori R; Whisenant, Jennifer G et al. (2014) Sequence design and evaluation of the reproducibility of water-selective diffusion-weighted imaging of the breast at 3?T. NMR Biomed 27:1030-6
Whisenant, Jennifer G; Ayers, Gregory D; Loveless, Mary E et al. (2014) Assessing reproducibility of diffusion-weighted magnetic resonance imaging studies in a murine model of HER2+ breast cancer. Magn Reson Imaging 32:245-9
Fluckiger, Jacob U; Loveless, Mary E; Barnes, Stephanie L et al. (2013) A diffusion-compensated model for the analysis of DCE-MRI data: theory, simulations and experimental results. Phys Med Biol 58:1983-98
Klomp, Dennis W J; Dula, Adrienne N; Arlinghaus, Lori R et al. (2013) Amide proton transfer imaging of the human breast at 7T: development and reproducibility. NMR Biomed 26:1271-7

Showing the most recent 10 out of 16 publications